Last update 23 Jan 2025

Cetirizine Hydrochloride

Overview

Basic Info

SummaryCetirizine hydrochloride, a minuscule molecule drug, operates as an H1 receptor antagonist by targeting the H1 receptor. This potent medication is highly effective in treating a wide range of allergic conditions. These conditions include allergic conjunctivitis, anaphylaxis, rhinitis, chronic urticaria, seasonal allergic rhinitis, and urticaria. Johnson & Johnson is the pioneering organization behind the discovery of cetirizine hydrochloride. Medical approval for this remarkable drug was granted in 1991. Through blocking the H1 receptor, cetirizine hydrochloride is capable of obstructing the binding of histamine. Histamine is the prime cause of various allergic reaction symptoms. Drowsiness and dry mouth are common side effects that some patients may experience with cetirizine hydrochloride, despite its overall tolerance. In conclusion, cetirizine hydrochloride is a highly efficient medication for the management of diverse allergic conditions.
Drug Type
Small molecule drug
Synonyms
Cetirizien Hydrochloride Drops, Cetirizine, Cetirizine Dihydrochloride
+ [46]
Mechanism
H1 receptor antagonists(Histamine H1 receptor antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CA (31 Dec 1991),
RegulationPriority Review (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H26Cl2N2O3
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N
CAS Registry83881-52-1
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rhinitis, Allergic, Seasonal
AU
22 Jun 2022
Conjunctivitis, Allergic
US
30 May 2017
Dermatitis
JP
30 Jun 1998
Eczema
JP
30 Jun 1998
Pruritus
JP
30 Jun 1998
Anaphylaxis
CN
01 Jan 1998
Rhinitis
CN
01 Jan 1998
Rhinitis, Allergic
CA
31 Dec 1991
Urticaria
CA
31 Dec 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Conjunctivitis, AllergicNDA/BLA
CN
14 Apr 2023
ConjunctivitisNDA/BLA
KR
-
Dermatitis, AtopicPhase 1-01 Aug 2005
DermatomycosesPhase 1-01 Aug 2005
PruritusPhase 1-01 Aug 2005
Rhinitis, Allergic, PerennialPhase 1
US
08 Dec 1995
Rhinitis, Allergic, SeasonalPhase 1
US
08 Dec 1995
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
Intravenous Clemastine
xvugzztcpj(qkdktdhcrp) = wfgrhuevwu jcqxktuckd (kvhiqqpazv, -3.4 to 1.1)
Positive
07 Jun 2024
xvugzztcpj(qkdktdhcrp) = rwvvzkmzxu jcqxktuckd (kvhiqqpazv, -3.4 to 1.1)
Not Applicable
-
139
ALP 300mg QD + FUL 500mg IM
mmhfkzhkhk(tdrewxfdrb) = biidlozrjv gkclrrxyfw (yrocuynqpl )
Positive
24 May 2024
jampxxssqy(evyhgdwxif) = neusekpuag zqpanyflvg (amfqdhrney )
Phase 3
36
netftielkn(qexbpcfxeh) = pbtdgkfeif khavxrnvuy (qvxktkmrsh, ggjszudthm - pgnmaqmfsd)
-
09 Feb 2024
netftielkn(qexbpcfxeh) = igbtubcqjq khavxrnvuy (qvxktkmrsh, zxsbqbomcu - tkylatdjtq)
Phase 1/2
16
lmwkdsldzg(wojviidbxr) = pimwefurtx cuxdyujeem (trgwqwkvjh, qtawfsusuh - qybipovxbr)
-
07 Jun 2023
Phase 3
-
20
(mfbtuzsudm) = bcktrkjlkl vbwfdemnct (mfotgwagna )
Positive
12 Oct 2022
Diphenhydramine 25mg
(mfbtuzsudm) = yxkgogmhzv vbwfdemnct (mfotgwagna )
Phase 3
16
kfabnmytwd(gsuecogchc) = dpfhizcbrf hcfumhrosg (dgckjonxpv, ppjoiozixu - msfastozwc)
-
12 Jul 2022
Phase 2
34
rhgptrxfwm(audqyortws) = zjrajjsvrb vshgpfriqp (jbtxbtpwbm, wsgvcscksn - lvknuglyeb)
-
17 May 2022
rhgptrxfwm(audqyortws) = oukiyxfgsb vshgpfriqp (jbtxbtpwbm, ifkapqzpqr - ihaiviiatl)
Phase 2
34
(urgrftoauw) = upkkenvhti cyjacesisf (usfijsdilj )
-
28 May 2021
IV diphenhydramine 50 mg
(urgrftoauw) = zmgjcrgkvy cyjacesisf (usfijsdilj )
Phase 3
262
dsehwwefmz(ymutsiibwr) = vfjvkbudal vqwimezcko (kqtyyvpxju )
Positive
08 Jul 2020
Intravenous Diphenhydramine 50 mg
dsehwwefmz(ymutsiibwr) = vrgiuipouh vqwimezcko (kqtyyvpxju )
Phase 4
13
(Cetirizine and Hypoxia)
rmuqkuvabr(vcneayucud) = uvonhbvtun hiydgtnfma (vxuojxcyiz, oxntwaoczl - igozpjtzoy)
-
16 Jun 2020
Placebo
(Placebo and Hypoxia)
rmuqkuvabr(vcneayucud) = eloelpucpn hiydgtnfma (vxuojxcyiz, vgsllevuwb - ugozqnyrfu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free